The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan

Peer Review reports

Original Submission
28 Sep 2016	Submitted	Original manuscript
10 Feb 2017	Reviewed	Reviewer Report - Cristina Martín-Arriscado
27 Apr 2017	Author responded	Author comments - Tao Chen
Resubmission - Version 2
27 Apr 2017	Submitted	Manuscript version 2
Publishing
4 May 2017	Editorially accepted
23 May 2017	Article published	10.1186/s13063-017-1976-6

Back to article page